{"id":"https://openalex.org/W26733326","doi":null,"title":"The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.","display_name":"The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.","publication_year":1992,"publication_date":"1992-02-01","ids":{"openalex":"https://openalex.org/W26733326","mag":"26733326","pmid":"https://pubmed.ncbi.nlm.nih.gov/1531829"},"language":"en","primary_location":{"id":"pmid:1531829","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/1531829","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of clinical psychiatry","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025999997","display_name":"Ian F. Tulloch","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"I F Tulloch","raw_affiliation_strings":["SmithKline Beecham Pharmaceuticals, Harlow, Essex, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"SmithKline Beecham Pharmaceuticals, Harlow, Essex, United Kingdom","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5105190514","display_name":"A M Johnson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A M Johnson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":7.294,"has_fulltext":false,"cited_by_count":82,"citation_normalized_percentile":{"value":0.97757671,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"53 Suppl","issue":null,"first_page":"7","last_page":"12"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/paroxetine","display_name":"paroxetine","score":1.0},{"id":"https://openalex.org/keywords/selective-serotonin-reuptake-inhibitors","display_name":"selective serotonin reuptake inhibitors","score":0.9940000176429749},{"id":"https://openalex.org/keywords/serotonin-reuptake-inhibition","display_name":"serotonin reuptake inhibition","score":0.8730000257492065},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9430000185966492},{"id":"https://openalex.org/keywords/first-pass-metabolism","display_name":"first-pass metabolism","score":0.9210000038146973},{"id":"https://openalex.org/keywords/drug-metabolites","display_name":"drug metabolites","score":0.5669999718666077},{"id":"https://openalex.org/keywords/antidepressants","display_name":"antidepressants","score":0.7089999914169312},{"id":"https://openalex.org/keywords/depression-treatment","display_name":"depression treatment","score":0.9340000152587891},{"id":"https://openalex.org/keywords/fluoxetine","display_name":"fluoxetine","score":0.6470000147819519},{"id":"https://openalex.org/keywords/sertraline","display_name":"sertraline","score":0.9070000052452087},{"id":"https://openalex.org/keywords/fluvoxamine","display_name":"fluvoxamine","score":0.9670000076293945}],"concepts":[{"id":"https://openalex.org/C2777828372","wikidata":"https://www.wikidata.org/wiki/Q408471","display_name":"Paroxetine","level":4,"score":0.967366635799408},{"id":"https://openalex.org/C2777669559","wikidata":"https://www.wikidata.org/wiki/Q407617","display_name":"Sertraline","level":4,"score":0.8972909450531006},{"id":"https://openalex.org/C2776134451","wikidata":"https://www.wikidata.org/wiki/Q422244","display_name":"Fluoxetine","level":4,"score":0.8083390593528748},{"id":"https://openalex.org/C2780092697","wikidata":"https://www.wikidata.org/wiki/Q7455053","display_name":"Serotonin reuptake inhibitor","level":4,"score":0.7266692519187927},{"id":"https://openalex.org/C2779910183","wikidata":"https://www.wikidata.org/wiki/Q409236","display_name":"Fluvoxamine","level":5,"score":0.7145918607711792},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7040810585021973},{"id":"https://openalex.org/C31487548","wikidata":"https://www.wikidata.org/wiki/Q4859664","display_name":"Reuptake inhibitor","level":4,"score":0.6851962208747864},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.5469605326652527},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.49416735768318176},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.48894965648651123},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.34448522329330444},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.22856420278549194},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.07362696528434753},{"id":"https://openalex.org/C2781161787","wikidata":"https://www.wikidata.org/wiki/Q48360","display_name":"Hippocampus","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D003866","descriptor_name":"Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D005473","descriptor_name":"Fluoxetine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D005473","descriptor_name":"Fluoxetine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D005473","descriptor_name":"Fluoxetine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D012702","descriptor_name":"Serotonin Antagonists","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D012702","descriptor_name":"Serotonin Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D012702","descriptor_name":"Serotonin Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014179","descriptor_name":"Neurotransmitter Uptake Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D014179","descriptor_name":"Neurotransmitter Uptake Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D014179","descriptor_name":"Neurotransmitter Uptake Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015057","descriptor_name":"1-Naphthylamine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D015057","descriptor_name":"1-Naphthylamine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D015057","descriptor_name":"1-Naphthylamine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D015057","descriptor_name":"1-Naphthylamine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016666","descriptor_name":"Fluvoxamine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D016666","descriptor_name":"Fluvoxamine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D016666","descriptor_name":"Fluvoxamine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D017374","descriptor_name":"Paroxetine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020280","descriptor_name":"Sertraline","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066298","descriptor_name":"In Vitro Techniques","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:1531829","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/1531829","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of clinical psychiatry","raw_type":"Journal Article"},{"id":"mag:26733326","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/1531829","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":5,"referenced_works":["https://openalex.org/W2078095800","https://openalex.org/W1975892163","https://openalex.org/W2048659949","https://openalex.org/W2107719587","https://openalex.org/W1697889386"],"related_works":["https://openalex.org/W2029479626","https://openalex.org/W3018957981","https://openalex.org/W2074050752","https://openalex.org/W2168235326","https://openalex.org/W2404383981","https://openalex.org/W2053168971","https://openalex.org/W2076884106","https://openalex.org/W2247831691","https://openalex.org/W2156890176","https://openalex.org/W2924885896"],"abstract_inverted_index":{"Paroxetine":[0,36],"is":[1,37,49,111],"a":[2,112],"highly":[3],"potent":[4,13],"and":[5,19,44,57,83,99],"selective":[6],"inhibitor":[7],"of":[8,55,61,80,89,122],"serotonin":[9],"reuptake,":[10],"being":[11],"more":[12],"in":[14,66],"vitro":[15],"than":[16],"fluoxetine,":[17],"fluvoxamine,":[18],"sertraline.":[20],"In":[21],"contrast":[22],"to":[23,77,115],"the":[24,41,53,59,116,120],"tricyclic":[25],"antidepressants,":[26],"paroxetine":[27,62,69,90,110],"has":[28],"little":[29],"affinity":[30],"for":[31,119],"catecholaminergic":[32],"or":[33],"histaminergic":[34],"systems.":[35],"well":[38],"absorbed":[39],"from":[40],"gastrointestinal":[42],"tract":[43],"undergoes":[45],"first-pass":[46],"metabolism":[47],"that":[48,109],"partially":[50],"saturable.":[51],"Unlike":[52],"metabolites":[54,60],"fluoxetine":[56],"sertraline,":[58],"are":[63,72,91],"pharmacologically":[64],"inactive":[65],"vivo.":[67],"Steady-state":[68],"plasma":[70],"concentrations":[71],"generally":[73],"achieved":[74],"within":[75],"4":[76],"14":[78],"days":[79],"commencing":[81],"therapy":[82],"remain":[84],"stable":[85],"thereafter.":[86],"The":[87],"pharmacokinetics":[88],"also":[92],"consistent":[93],"with":[94,104],"once-daily":[95],"dosing.":[96],"This":[97],"pharmacologic":[98],"pharmacokinetic":[100],"profile,":[101],"taken":[102],"together":[103],"extensive":[105],"clinical":[106],"data,":[107],"indicates":[108],"valuable":[113],"addition":[114],"physician's":[117],"armamentarium":[118],"treatment":[121],"depression.":[123]},"counts_by_year":[{"year":2021,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}